Brands in de­mand: Keytru­da, Dupix­ent and Ozem­pic lead 2023 new sales pre­dic­tions — Eval­u­ate re­port

What’s old is new again for 2023 when it comes to phar­ma drug brands added sales this year. Led by Mer­ck’s Keytru­da and Sanofi and Re­gen­eron’s Dupix­ent, the biggest new sales gen­er­a­tors are most­ly from al­ready es­tab­lished drugs, ac­cord­ing to Eval­u­ate Phar­ma’s an­nu­al fore­cast.

On­ly two of the top 10 on the list are new 2022 FDA ap­provals — Eli Lil­ly’s Moun­jaro at No. 4 and No­vo Nordisk’s We­govy at No. 6.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER